None listed
Conditions
Brief summary
Study hypothesis: That priming the cardiopulmonary bypass pump with Hartmann's solution rather than Ringer's Injection will decrease the amount of acidosis associated with cardiopulmonary bypass.
Interventions
Patients randomized to cardiopulmonary bypass primed with either 1500ml of Ringer’s Injection(Baxter, Sydney Australia): sodium 144 mmol/L, potassium 4 mmol/L , calcium 2 mmol/L , and chloride 152 mmol/L; OR 1500ml of Hartmann’s solution (Baxter, Sydney, Australia): sodium 129 mmol/L, potassium 5 mmol/L, calcium 2 mmol/L , chloride 109 mmol/L, and lactate 29 mmol/L .
Patients will recieve one dose only of either the Ringer's Injection prime or Hartmann's prime when cardiopulmonary bypass is
Patients randomized to cardiopulmonary bypass primed with either 1500ml of Ringer’s Injection(Baxter, Sydney Australia): sodium 144 mmol/L, potassium 4 mmol/L , calcium 2 mmol/L , and chloride 152 mmol/L; OR 1500ml of Hartmann’s solution (Baxter, Sydney, Australia): sodium 129 mmol/L, potassium 5 mmol/L, calcium 2 mmol/L , chloride 109 mmol/L, and lactate 29 mmol/L . Patients will recieve one dose only of either the Ringer's Injection prime or Hartmann's prime when cardiopulmonary bypass is initiated.
Sponsors
Associate Professor David Story
Austin Health
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Adults undergoing elective primary coronary artery bypass surgery.
Exclusion criteria
Patient declines, age less than 18 years, age greater than 75 years, creatinine concentration greater than 150 micromoles/L, diabetes mellitus, anaemia (hemoglobin level <100g/L), pre-existing acid-base abnormalities, and extremes in weight (body weight <50kg or >100kg.
Outcome results
None listed